TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

NCT07052903

Status	RECRUITING
Phase	Phase 3
Sponsor	Alnylam Pharmaceuticals
Enrollment	1,250 participants

Key Eligibility Criteria

Inclusion (4)

- Has documented diagnosis of ATTR amyloidosis with cardiomyopathy including those with hereditary ATTR (hATTR) or wild-type ATTR (wATTR) amyloidosis.
- Has medical history of heart failure (HF) with at least 1 prior hospitalization for HF or signs and symptoms that require treatment with a diuretic.
- Has screening N-terminal prohormone B-type natriuretic peptide (NT-proBNP) \>300 ng/L and \<8500 ng/L; In patients with permanent or persistent atrial fibrillation, screening NT-proBNP \>600 ng/L and \<8500 ng/L.
- Patients may be receiving approved TTR stabilizers for ATTR amyloidosis (eg, tafamidis, acoramidis) and may be receiving background therapy for HF at the discretion of the Investigator.

Exclusion (4)

- Has New York Heart Association (NYHA) Class IV HF; or NYHA Class III heart failure AND ATTR Amyloidosis Disease Stage 3.
- Has a polyneuropathy disability (PND) Score IIIa, IIIb, or IV.
- Has an estimated glomerular filtration rate eGFR of \<30 mL/min/1.73m\^2 at screening.
- Has received prior or currently receiving TTR-lowering therapy

Locations (157 total)

Clinical Trial Site, La Jolla, California, United States
Clinical Trial Site, Washington D.C., District of Columbia, United States
Clinical Trial Site, Brandon, Florida, United States
... and 154 more locations